ClinicalTrials.gg
CompletedNCT02058589Updated Aug 1, 2018Results posted

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal Transplant

A Phase 3 interventional study of Herpes Zoster vaccine GSK1437173A and Placebo in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 34 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-01.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
265
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.

Enrollment
22nd of 46
265 · median 239
Started
2014
with 4 others
Phase 3
22 of 46
2 open now
Registered
14th of 46
by date
Lead sponsor
26 of 46
GlaxoSmithKline

Among the 46 studies testing shingrix in Herpes Zoster, this one is the 22nd largest by enrollment, is one of 5 that started in 2014, is one of 22 in phase 3, and was the 14th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About shingrix

shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing shingrix in Herpes Zoster, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine administered on a 0- and 1- to 2-months schedule in adults 18 years of age or older who are receiving chronic immunosuppressive therapy.

03

Conditions studied

  • Herpes Zoster

Browse trials for

Keywords

  • Immunocompromised
  • Safety
  • ≥ 18 years of age
  • Renal transplant
  • Adults
  • Immunosuppressed
  • Immunogenicity
  • Herpes zoster
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • A male or female, aged 18 years or older and having reached the age of legal consent, on the date the is signed.
  • Written informed consent obtained from the subject.
  • Subject who has received an ABO compatible allogeneic renal transplant.
  • Subject receiving maintenance therapy for the prevention of allograft rejection for a minimum of one month (30 days) prior to the first vaccination.
  • Subject without an episode of allograft rejection over the previous three months (90 days) prior to the first vaccination.
  • Subject with stable renal function, stability defined as:

    • less than 20% variability between last two creatinine measurements or calculated
    • or in the opinion of the investigator after investigator review of more than the last two creatinine measurements or calculated GFRs.
  • Subject not less than 4 months (120 days) and not more than 18 months (547 days) after allograft transplantation at the time of the first vaccination.
  • Subjects with multiple dialysis options (peritoneal and/or more than one anatomical access site for haemodialysis) in the event acute or chronic dialysis is needed.
  • Female subjects of non- may be enrolled in the study.
  • Female subjects of childbearing potential may be enrolled in the study, if the subject:

    • has practiced adequate for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of the first vaccination, and
    • has agreed to continue adequate contraception during the primary treatment period and for 2 months after completion of the vaccination series.

Exclusion criteria

Exclusion Criteria:

  • Any primary kidney disease with a high incidence of recurrent primary kidney disease.
  • Evidence of recurrent primary kidney disease within the current allograft.
  • Previous allograft loss secondary to recurrent primary kidney disease.

    • Multiple kidney transplants are allowed if the reason for a previous allograft's loss is not recurrent primary kidney disease.
  • More than one organ transplanted (i.e. kidney-liver, double kidney or kidney-other organ(s) transplanted).
  • History of events that, in the opinion of the investigator, may put subject at increased risk for chronic allograft dysfunction (e.g. delayed graft function, peri-operative complications).
  • Histologic reports of chronic allograft injury (e.g. transplant glomerulopathy, arteriopathy, C4d deposition).
  • Evidence of significant proteinuria in the opinion of the investigator.
  • Panel reactive antibody score (PRA or cPRA) that is unknown at the time of transplant.
  • Any or potential immune-mediated disease including primary kidney disease.
  • Use of anti-CD20 or other B-cell monoclonal antibody agents (e.g., rituximab) as induction, maintenance and/or therapeutic therapy for the prevention of allograft rejection within 9 months (274 days) of first dose of study vaccine/placebo.
  • Use of any or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine/placebo, or planned use during the study period.
  • Concurrent or planned participation in another clinical study, at any time during the study period, which has exposed or will expose the subject to an investigational or a non-registered product
  • Administration or planned administration of a within 30 days prior to the first dose of study vaccine and ending 30 days after the last dose of study vaccine, or, administration or planned administration of a non-replicating vaccine within 8 days prior to or within 14 days after either dose of study vaccine.
  • Planned administration during the study of a varicella or HZ vaccine other than the study vaccine.
  • Previous vaccination against HZ or varicella within the 12 months preceding the first dose of study vaccine/placebo.
  • Occurrence of varicella or HZ per clinical history, within the 12 months preceding the first dose of study vaccine/placebo.
  • Failure to fully complete the 7-day pre-vaccination diary card distributed at the Pre-vaccination visit.
  • Evidence or high suspicion, in the opinion of the investigator, of noncompliance or nonadherence to use of induction and/or maintenance immunosuppressive therapies.
  • Any confirmed or suspected , primary immunodeficiency disease, disseminated or untreated , or systemic infection.
  • History of any reaction or likely to be exacerbated by any component of the vaccine or study material and equipment.
  • Any condition which, in the judgment of the investigator, would make intramuscular injection unsafe.
  • Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study.
  • Acute disease and/or fever at the time of vaccination.

    • Fever is defined as temperature ≥ 37.5°C /99.5°F by oral route. The preferred route for recording temperature in this study will be oral.
    • Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator.
  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue precautions (if of ) before Month 3.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
265 participants (actual)

Study arms

  • Experimental
    GSK1437173A Group

    Subjects, aged 18 years or older, received 2 doses of the GSK 1437173A vaccine, adjuvanted with AS01B at Day 0, and Month 1, administered intramuscularly, in the deltoid muscle of an arm.

    Biological: Herpes Zoster vaccine GSK1437173A

  • Placebo comparator
    Placebo Group

    Subjects, aged 18 years or older, received 2 doses of Placebo (lyophilised sucrose reconstituted with saline \[NaCl\] solution) at Day 0, and Month 1, administered intramuscularly, in the deltoid muscle of an arm.

    Drug: Placebo

Interventions

  • 2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.

  • DrugPlacebo

    2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.

06

What researchers measure

Primary outcomes

  1. Number of Subjects With a Vaccine Response for Anti-glycoprotein E (gE) Humoral Immunogenicity

    Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination greater than or equal to (≥) 4 fold the cut-off for Anti-gE (4x97 milli-international units per milliliter \[mIU/ml\]); For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration. Vaccine response was determined by Enzyme-Linked ImmunoSorbent Assay (ELISA).

    Time frame: At Month 2.

  2. Number of Subjects With Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = Pain when limb was moved, which prevented everyday activities. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

    Time frame: Within 7 days (Days 0-6) after each dose and across doses.

  3. Days With Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling.

    Time frame: Within 7 days (Days 0-6) after each dose and overall/dose

  4. Number of Subjects With Solicited General Symptoms

    Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\] . Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. Gastrointestinal symptoms (Gastro. sympt.) included nausea, vomiting, diarrhoea and/or abdominal pain.

    Time frame: Within 7 days (Days 0-6) after each dose and across doses

  5. Days With Solicited General Symptoms

    Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\].

    Time frame: Within 7 days (Days 0-6) after each dose and overall/dose

  6. Number of Subjects With Unsolicited Symptoms (AEs)

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

    Time frame: During the 30-day (Days 0-29) post-vaccination period

  7. Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs)

    pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology

    Time frame: From first vaccination (Month 0) up to 1 month post last vaccination (Month 2).

  8. Number of Subjects With Any and Related Serious Adverse Events (SAEs)

    SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongatoion of hospitalization, or result in disability /incapacity. Related = SAE assessed by the investigator as related to the vaccination.

    Time frame: From first vaccination (Month 0) up to 1 month post last vaccination (Month 2).

  9. Number of Subjects With Renal Allograft Rejection

    Renal allograft rejection was confirmed through biopsy.

    Time frame: From the first vaccination (Month 0) up to 1 month post last vaccination (Month 2).

  10. Number of Subjects With Changes in Allograft Function

    Allograft function was indicated by the increase in levels of serum creatinine (≥ 1.20, ≥ 1.50, ≥ 1.75 or ≥ 2 fold increase). The number of subjects with declining allograft function, as determined by serum creatinine measurements post-vaccination (up to 30 days post-last vaccination) compared to pre-vaccination were presented.

    Time frame: From the first vaccination (Month 0) up to 1 month post last vaccination (Month 2).

Secondary outcomes

  1. Anti-gE Antibody Concentrations

    Varicella Zoster Virus (VZV) gE antibody Immunoglobulin G concentrations were determined by ELISA assay, presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The reference seropositivity cut-off value was ≥ 97 mIU/mL.

    Time frame: At Months 0, 1, 2, 7 and 13

  2. Number of Subjects With a Vaccine Response for Anti-gE Humoral Immunogenicity

    Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination greater than or equal to (≥) 4 fold the cut-off for Anti-gE (4x97 mIU/mL); For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration. Vaccine response was determined by ELISA.

    Time frame: At Months 1, 7 and 13

  3. Frequencies of gE-specific Cluster of Differentiation 4 (CD4+) T-cells

    Descriptive statistics of gE-specific CD4+ T-cells, expressing at least two activation markers (from among interferon gamma \[IFN-γ\], interleukin-2 \[IL-2\], tumour necrosis factor alpha \[TNF-α\] and cluster of differentiation 40-ligand \[CD40L\]) were tabulated, as determined by in vitro Intracellular Cytokine Staining (ICS).

    Time frame: At Months 0, 2 and 13

  4. Number of Subjects With a Vaccine Response for gE-specific CD4+ T-cells

    Vaccine response for gE-specific CD4+ T-cells expressing at least two activation markers (from among IFN-γ, IL-2, TNF-α and CD40L), was determined by in vitro ICS. Vaccine response was defined as: For initially subjects with pre-vaccination T-cell frequencies below the threshold, at least a 2-fold increase as compared to the threshold (2x\<320\> Events/10 million CD4+ T-cells); For initially subjects with pre-vaccination T-cell frequencies above the threshold, at least a 2-fold increase as compared to pre-vaccination T-cell frequencies.

    Time frame: At Months 2 and 13

  5. Number of Subjects With Any and Related SAEs

    SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related = SAE assessed by the investigator as related to the vaccination.

    Time frame: From 1 month post last vaccination (Month 2) until study end (Month 13).

  6. Number of Subjects With Any pIMDs

    pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

    Time frame: From 1 month post last vaccination (Month 2) until study end (Month 13).

  7. Number of Subjects With Renal Allograft Rejection

    Renal allograft rejection was confirmed through biopsy.

    Time frame: From 1 month post last vaccination (Month 2) until study end (Month 13).

  8. Number of Subjects With Changes in Allograft Function

    Allograft function was indicated by the increase in levels of serum creatinine (≥ 1.20, ≥ 1.50, ≥ 1.75 or ≥ 2 fold increase). The number of subjects with declining allograft function, as determined by serum creatinine measurements post-vaccination (from 30 days post-last vaccination up to study end) compared to pre-vaccination were presented.

    Time frame: From 1 month post last vaccination (Month 2) until study end (Month 13)

07

Results

Posted Aug 1, 2018

Participant flow

Participant flow — Overall Study
MilestoneGSK1437173A GroupControl Group
Started132132
Completed130130
Not completed22
Withdrew: Serious adverse event11
Withdrew: Non-serious adverse event10
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryNumber of Subjects With a Vaccine Response for Anti-glycoprotein E (gE) Humoral Immunogenicity

Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination greater than or equal to (≥) 4 fold the cut-off for Anti-gE (4x97 milli-international units per milliliter \[mIU/ml\]); For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration. Vaccine response was determined by Enzyme-Linked ImmunoSorbent Assay (ELISA).

Time frame:
At Month 2.
Reported as:
Count of participants · Participants
Number of Subjects With a Vaccine Response for Anti-glycoprotein E (gE) Humoral Immunogenicity
ParticipantsGSK1437173A GroupControl Group
Number of Subjects With a Vaccine Response for Anti-glycoprotein E (gE) Humoral Immunogenicity975
PrimaryNumber of Subjects With Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = Pain when limb was moved, which prevented everyday activities. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

Time frame:
Within 7 days (Days 0-6) after each dose and across doses.
Reported as:
Count of participants · Participants
Number of Subjects With Solicited Local Symptoms
ParticipantsGSK1437173A GroupControl Group
Any Pain, Dose 11078
Grade 3 Pain, Dose 1100
Any Redness, Dose 1241
Grade 3 Redness, Dose 100
Any Swelling, Dose 1101
Grade 3 Swelling, Dose 100
Any Pain, Dose 2936
Grade 3 Pain, Dose 290
Any Redness, Dose 2211
Grade 3 Redness, Dose 210
Any Swelling, Dose 2110
Grade 3 Swelling, Dose 210
Any Pain, Across doses11411
Grade 3 Pain, Across doses130
Any Redness, Across doses332
Grade 3 Redness, Across doses10
Any Swelling, Across doses151
Grade 3 Swelling, Across doses10
PrimaryDays With Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling.

Time frame:
Within 7 days (Days 0-6) after each dose and overall/dose
Reported as:
Median · Days
Days With Solicited Local Symptoms
DaysGSK1437173A GroupControl Group
Pain, Dose 13.0 (2.0 to 4.0)1.5 (1.0 to 2.5)
Pain, Dose 23.0 (2.0 to 3.0)1.0 (1.0 to 2.0)
Pain, Overall3.0 (2.0 to 4.0)1.0 (1.0 to 2.0)
Redness, Dose 14.0 (2.5 to 6.5)4.0 (4.0 to 4.0)
Redness, Dose 23.0 (2.0 to 7.0)2.0 (2.0 to 2.0)
Redness, Overall4.0 (2.0 to 7.0)3.0 (2.0 to 4.0)
Swelling, Dose 14.0 (2.0 to 7.0)4.0 (4.0 to 4.0)
Swelling, Dose 24.0 (1.0 to 5.0)—
Swelling, Overall4.0 (2.0 to 6.0)4.0 (4.0 to 4.0)
PrimaryNumber of Subjects With Solicited General Symptoms

Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\] . Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. Gastrointestinal symptoms (Gastro. sympt.) included nausea, vomiting, diarrhoea and/or abdominal pain.

Time frame:
Within 7 days (Days 0-6) after each dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Solicited General Symptoms
ParticipantsGSK1437173A GroupControl Group
Any Fatigue, Dose 14742
Grade 3 Fatigue, Dose 133
Related Fatigue, Dose 182
Any Gastro. sympt., Dose 11716
Grade 3 Gastro. sympt., Dose 110
Related Gastro. sympt., Dose 111
Any Headache, Dose 13225
Grade 3 Headache, Dose 114
Related Headache, Dose 153
Any Myalgia, Dose 14323
Grade 3 Myalgia, Dose 141
Related Myalgia, Dose 1112
Any Shivering, Dose 11013
Grade 3 Shivering, Dose 101
Related Shivering, Dose 132
Any Temperature, Dose 1136
Grade 3 Temperature, Dose 100
Related Temperature, Dose 130
Any Fatigue, Dose 24936
Grade 3 Fatigue, Dose 244
Related Fatigue, Dose 284
Any Gastro. sympt., Dose 21414
Grade 3 Gastro. sympt., Dose 201
Related Gastro. sympt., Dose 212
Any Headache, Dose 23522
Grade 3 Headache, Dose 223
Related Headache, Dose 291
Any Myalgia, Dose 24719
Grade 3 Myalgia, Dose 283
Related Myalgia, Dose 2143
Any Shivering, Dose 2239
Grade 3 Shivering, Dose 242
Related Shivering, Dose 290
Any Temperature, Dose 2217
Grade 3 Temperature, Dose 210
Related Temperature, Dose 260
Any Fatigue, Across doses6253
Grade 3 Fatigue, Across doses46
Related Fatigue, Across doses154
Any Gastro. sympt., Across doses2424
Grade 3 Gastro. sympt., Across doses11
Related Gastro. sympt.,Across doses23
Any Headache, Across doses4434
Grade 3 Headache, Across doses25
Related Headache, Across doses124
Any Myalgia, Dose Across doses6531
Grade 3 Myalgia, Dose Across doses93
Related Myalgia, Dose Across doses214
Any Shivering, Dose Across doses2916
Grade 3 Shivering, Dose Across doses42
Related Shivering, Dose Across doses112
Any Temperature, Dose Across doses3113
Grade 3 Temperature, Dose Across doses10
Related Temperature, Dose Across doses90
PrimaryDays With Solicited General Symptoms

Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\].

Time frame:
Within 7 days (Days 0-6) after each dose and overall/dose
Reported as:
Median · Days
Days With Solicited General Symptoms
DaysGSK1437173A GroupControl Group
Fatigue, Dose 13.0 (2.0 to 6.0)3.0 (1.0 to 7.0)
Fatigue, Dose 23.0 (2.0 to 5.0)4.5 (2.0 to 7.0)
Fatigue, Overall3.0 (2.0 to 5.5)4.0 (2.0 to 7.0)
Gastrointestinal symptoms, Dose 12.0 (1.0 to 2.0)3.5 (1.0 to 4.5)
Gastrointestinal symptoms, Dose 22.0 (1.0 to 2.0)2.0 (1.0 to 3.0)
Gastrointestinal symptoms, Overall2.0 (1.0 to 2.0)2.0 (1.0 to 4.0)
Headache, Dose 11.0 (1.0 to 2.0)2.0 (1.0 to 3.0)
Headache, Dose 22.0 (1.0 to 3.0)2.0 (1.0 to 4.0)
Headache, Overall2.0 (1.0 to 3.0)2.0 (1.0 to 3.0)
Myalgia, Dose 13.0 (2.0 to 4.0)3.0 (1.0 to 7.0)
Myalgia, Dose 22.0 (1.0 to 4.0)7.0 (2.0 to 7.0)
Myalgia, Overall3.0 (1.0 to 4.0)5.0 (1.0 to 7.0)
Shivering, Dose 12.0 (1.0 to 4.0)2.0 (1.0 to 7.0)
Shivering, Dose 21.0 (1.0 to 2.0)3.0 (2.0 to 7.0)
Shivering, Overall1.0 (1.0 to 2.0)2.5 (1.0 to 7.0)
Temperature, Dose 11.0 (1.0 to 1.0)1.0 (1.0 to 1.0)
Temperature, Dose 21.0 (1.0 to 1.0)1.0 (1.0 to 1.0)
Temperature, Overall1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)
PrimaryNumber of Subjects With Unsolicited Symptoms (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

Time frame:
During the 30-day (Days 0-29) post-vaccination period
Reported as:
Count of participants · Participants
Number of Subjects With Unsolicited Symptoms (AEs)
ParticipantsGSK1437173A GroupControl Group
At least one symptom5144
Subjects with grade 3 AEs75
Subjects with related AEs73
PrimaryNumber of Subjects With Any Potential Immune-mediated Diseases (pIMDs)

pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology

Time frame:
From first vaccination (Month 0) up to 1 month post last vaccination (Month 2).
Reported as:
Count of participants · Participants
Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs)
ParticipantsGSK1437173A GroupControl Group
Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs)00
PrimaryNumber of Subjects With Any and Related Serious Adverse Events (SAEs)

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongatoion of hospitalization, or result in disability /incapacity. Related = SAE assessed by the investigator as related to the vaccination.

Time frame:
From first vaccination (Month 0) up to 1 month post last vaccination (Month 2).
Reported as:
Count of participants · Participants
Number of Subjects With Any and Related Serious Adverse Events (SAEs)
ParticipantsGSK1437173A GroupControl Group
Any SAEs65
Related SAEs00
PrimaryNumber of Subjects With Renal Allograft Rejection

Renal allograft rejection was confirmed through biopsy.

Time frame:
From the first vaccination (Month 0) up to 1 month post last vaccination (Month 2).
Reported as:
Count of participants · Participants
Number of Subjects With Renal Allograft Rejection
ParticipantsGSK1437173A GroupControl Group
Rejection confirmed00
Rejection not confirmed03
PrimaryNumber of Subjects With Changes in Allograft Function

Allograft function was indicated by the increase in levels of serum creatinine (≥ 1.20, ≥ 1.50, ≥ 1.75 or ≥ 2 fold increase). The number of subjects with declining allograft function, as determined by serum creatinine measurements post-vaccination (up to 30 days post-last vaccination) compared to pre-vaccination were presented.

Time frame:
From the first vaccination (Month 0) up to 1 month post last vaccination (Month 2).
Reported as:
Count of participants · Participants
Number of Subjects With Changes in Allograft Function
ParticipantsGSK1437173A GroupControl Group
≥1.20 fold increase57
≥1.50 fold increase01
≥1.75 fold increase01
≥2 fold increase01
SecondaryAnti-gE Antibody Concentrations

Varicella Zoster Virus (VZV) gE antibody Immunoglobulin G concentrations were determined by ELISA assay, presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The reference seropositivity cut-off value was ≥ 97 mIU/mL.

Time frame:
At Months 0, 1, 2, 7 and 13
Reported as:
Geometric mean · mIU/mL
Anti-gE Antibody Concentrations
mIU/mLGSK1437173A GroupControl Group
anti-gE, Month 01354.4 (1118.3 to 1640.4)1495.7 (1202.3 to 1860.8)
anti-gE, Month 19530.5 (7111.3 to 12772.7)1501.9 (1231.3 to 1832.0)
anti-gE, Month 219163.8 (15041.5 to 24416.0)1489.4 (1215.8 to 1824.7)
anti-gE, Month 713066.7 (10291.5 to 16590.4)1533.7 (1249.6 to 1882.3)
anti-gE, Month 138545.1 (6753.7 to 10811.5)1572.7 (1269.6 to 1948.1)
SecondaryNumber of Subjects With a Vaccine Response for Anti-gE Humoral Immunogenicity

Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination greater than or equal to (≥) 4 fold the cut-off for Anti-gE (4x97 mIU/mL); For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration. Vaccine response was determined by ELISA.

Time frame:
At Months 1, 7 and 13
Reported as:
Count of participants · Participants
Number of Subjects With a Vaccine Response for Anti-gE Humoral Immunogenicity
ParticipantsGSK1437173A GroupControl Group
anti-gE, Month 1773
anti-gE, Month 7835
anti-gE, Month 13747
SecondaryFrequencies of gE-specific Cluster of Differentiation 4 (CD4+) T-cells

Descriptive statistics of gE-specific CD4+ T-cells, expressing at least two activation markers (from among interferon gamma \[IFN-γ\], interleukin-2 \[IL-2\], tumour necrosis factor alpha \[TNF-α\] and cluster of differentiation 40-ligand \[CD40L\]) were tabulated, as determined by in vitro Intracellular Cytokine Staining (ICS).

Time frame:
At Months 0, 2 and 13
Reported as:
Mean · gE-specific CD4+ T-cells/million T-cells
Frequencies of gE-specific Cluster of Differentiation 4 (CD4+) T-cells
gE-specific CD4+ T-cells/million T-cellsGSK1437173A GroupControl Group
Month 0110.9 ± 182.09165.75 ± 242.92
Month 22433.07 ± 2102.29156.98 ± 274.81
Month 131320.92 ± 1823.64129.41 ± 197.92
SecondaryNumber of Subjects With a Vaccine Response for gE-specific CD4+ T-cells

Vaccine response for gE-specific CD4+ T-cells expressing at least two activation markers (from among IFN-γ, IL-2, TNF-α and CD40L), was determined by in vitro ICS. Vaccine response was defined as: For initially subjects with pre-vaccination T-cell frequencies below the threshold, at least a 2-fold increase as compared to the threshold (2x\<320\> Events/10 million CD4+ T-cells); For initially subjects with pre-vaccination T-cell frequencies above the threshold, at least a 2-fold increase as compared to pre-vaccination T-cell frequencies.

Time frame:
At Months 2 and 13
Reported as:
Count of participants · Participants
Number of Subjects With a Vaccine Response for gE-specific CD4+ T-cells
ParticipantsGSK1437173A GroupControl Group
Month 2200
Month 13170
SecondaryNumber of Subjects With Any and Related SAEs

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related = SAE assessed by the investigator as related to the vaccination.

Time frame:
From 1 month post last vaccination (Month 2) until study end (Month 13).
Reported as:
Count of participants · Participants
Number of Subjects With Any and Related SAEs
ParticipantsGSK1437173A GroupControl Group
Any SAEs2129
Related SAEs01
SecondaryNumber of Subjects With Any pIMDs

pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

Time frame:
From 1 month post last vaccination (Month 2) until study end (Month 13).
Reported as:
Count of participants · Participants
Number of Subjects With Any pIMDs
ParticipantsGSK1437173A GroupControl Group
Number of Subjects With Any pIMDs42
SecondaryNumber of Subjects With Renal Allograft Rejection

Renal allograft rejection was confirmed through biopsy.

Time frame:
From 1 month post last vaccination (Month 2) until study end (Month 13).
Reported as:
Count of participants · Participants
Number of Subjects With Renal Allograft Rejection
ParticipantsGSK1437173A GroupControl Group
Rejection confirmed47
Rejection not confirmed1213
SecondaryNumber of Subjects With Changes in Allograft Function

Allograft function was indicated by the increase in levels of serum creatinine (≥ 1.20, ≥ 1.50, ≥ 1.75 or ≥ 2 fold increase). The number of subjects with declining allograft function, as determined by serum creatinine measurements post-vaccination (from 30 days post-last vaccination up to study end) compared to pre-vaccination were presented.

Time frame:
From 1 month post last vaccination (Month 2) until study end (Month 13)
Reported as:
Count of participants · Participants
Number of Subjects With Changes in Allograft Function
ParticipantsGSK1437173A GroupControl Group
≥1.20 fold increase1722
≥1.50 fold increase43
≥1.75 fold increase31
≥2 fold increase20

Adverse events

Collected over Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period, Unsolicited symptoms: during the 30-day (Days 0-29) post-vaccination period, Serious Adverse Events: from Month 0 up to study end at Month 13.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK1437173A Group1/132 (0.8%)26/132 (19.7%)121/132 (91.7%)
Placebo Group1/132 (0.8%)33/132 (25%)78/132 (59.1%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
EventGSK1437173A GroupPlacebo Group
Transplant rejectionImmune system disorders2/1324/132
GastroenteritisInfections and infestations2/1324/132
Herpes zosterInfections and infestations0/1324/132
Pyelonephritis acuteInfections and infestations4/1321/132
InfluenzaInfections and infestations3/1320/132
Urinary tract infectionInfections and infestations2/1323/132
Blood creatinine increasedInvestigations0/1323/132
Kidney transplant rejectionImmune system disorders1/1322/132
Febrile neutropeniaBlood and lymphatic system disorders0/1321/132
Atrial fibrillationCardiac disorders0/1321/132
Most frequent other events
Most frequent other events
EventGSK1437173A GroupPlacebo Group
PainGeneral disorders114/13211/132
MyalgiaMusculoskeletal and connective tissue disorders65/13231/132
FatigueGeneral disorders62/13254/132
HeadacheNervous system disorders44/13235/132
ErythemaSkin and subcutaneous tissue disorders33/1322/132
PyrexiaGeneral disorders32/13214/132
ChillsGeneral disorders29/13216/132
Gastrointestinal disorderGastrointestinal disorders24/13224/132
SwellingGeneral disorders15/1321/132

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GSK1437173A GroupControl GroupTotal
Geometric mean52.3 ± 12.552.4 ± 12.852.4 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)GSK1437173A GroupControl GroupTotal
Female384179
Male9491185
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GSK1437173A GroupControl GroupTotal
African Heritage / African American314
Asian - Central/South Asian Heritage123
Asian - East Asian Heritage202242
Asian - Japanese Heritage011
Asian - South East Asian Heritage10313
White - Arabic / North African Heritage224
White - Caucasian / European Heritage8897185
Unspecified8412
08

Study locations

34 sites
  • GSK Investigational Site
    Brussels, 1200, Belgium
  • GSK Investigational Site
    Bruxelles, 1090, Belgium
  • GSK Investigational Site
    Gent, 9000, Belgium
  • GSK Investigational Site
    Leuven, 3000, Belgium
  • GSK Investigational Site
    Edmonton, Alberta T6G 2B7, Canada
  • GSK Investigational Site
    Halifax, Nova Scotia B3K 6R8, Canada
  • GSK Investigational Site
    Toronto, Ontario M5B 1W8, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2N2, Canada
  • GSK Investigational Site
    Hradec Kralove, 536 00, Czechia
  • GSK Investigational Site
    Helsinki, 00029, Finland
  • GSK Investigational Site
    Parma, Emilia-Romagna 43126, Italy
  • GSK Investigational Site
    Genova, Liguria 16132, Italy
  • GSK Investigational Site
    Milano, Lombardia 20132, Italy
  • GSK Investigational Site
    Siena, Toscana 53100, Italy
  • GSK Investigational Site
    Treviso, Veneto 31100, Italy
  • GSK Investigational Site
    Seoul, 135-710, Korea, Republic of
  • GSK Investigational Site
    Seoul, 137-701, Korea, Republic of
  • GSK Investigational Site
    Panama, Panama
  • GSK Investigational Site
    Barakaldo (Vizcaya), 48903, Spain
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Barcelona, 08036, Spain
  • GSK Investigational Site
    Cordoba, 14004, Spain
  • GSK Investigational Site
    Hospitalet de Llobregat, 08907, Spain
  • GSK Investigational Site
    Madrid, 28007, Spain
  • GSK Investigational Site
    Madrid, 28034, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Santander, 39008, Spain
  • GSK Investigational Site
    Sevilla, 41013, Spain
  • GSK Investigational Site
    Kaohsiung, 833, Taiwan
  • GSK Investigational Site
    Keelung, 204, Taiwan
  • GSK Investigational Site
    Taichung, 407, Taiwan
  • GSK Investigational Site
    Taipei, 100, Taiwan
  • GSK Investigational Site
    Taoyuan, 333, Taiwan
09

References and documents

Publications

  • Vink P, Ramon Torrell JM, Sanchez Fructuoso A, Kim SJ, Kim SI, Zaltzman J, Ortiz F, Campistol Plana JM, Fernandez Rodriguez AM, Rebollo Rodrigo H, Campins Marti M, Perez R, Gonzalez Roncero FM, Kumar D, Chiang YJ, Doucette K, Pipeleers L, Aguera Morales ML, Rodriguez-Ferrero ML, Secchi A, McNeil SA, Campora L, Di Paolo E, El Idrissi M, Lopez-Fauqued M, Salaun B, Heineman TC, Oostvogels L; Z-041 Study Group. Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial. Clin Infect Dis. 2020 Jan 2;70(2):181-190. doi: 10.1093/cid/ciz177. PubMed 30843046 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in May 2016, 25 months.

Results were first posted in Aug 2018, 2 years 2 months after primary completion.

Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 25 months is above that.

Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2014
First posted
Feb 10, 2014
StartActual
Mar 20, 2014
Primary completionActual
May 11, 2016
CompletionActual
Apr 13, 2017
Results first posted
Aug 1, 2018
Last update
Aug 1, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02058589
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 10, 2014
Start date
Mar 20, 2014
Primary completion
May 11, 2016
Completion
Apr 13, 2017
Results posted
Aug 1, 2018
Last update
Aug 1, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion